Adam Goulburn

Adam Goulburn, Partner, Lux Capital

Adam invests at the intersection of biology, healthcare, technology and data. He is interested in the digitization of healthcare; genomics and coding biology; the microbiome; bionics and cyborgs; neuroscience and brain-computer interfaces; next-gen bio-imaging; regenerative medicine; synthetic biology; human performance; and other areas of applied hard sciences.

Over the past decade, Adam has been an integral part of the firm’s life sciences investments, focusing on futuristic ventures at the edge of possibility. Adam founded and incubated a number of Lux companies including Cajal Neuroscience and VNV Bio. He was also the founding CEO and investor in Kallyope, which combines bioinformatics, sequencing, neuroimaging and molecular biology to decode the gut-brain axis. In addition, Adam was a founding investor in Eikon Therapeutics, which deploys next-generation microscopy and single-molecule imaging for high-throughput drug discovery.

Fascinated with the potential of digitization in life sciences and the broader healthcare ecosystem, Adam has led a number of investments in healthcare technology companies, including Science 37 (virtual clinical trials), RDMD (acceleration of rare disease drug discovery) and Rivet (healthcare payment transparency platform). Adam also led Lux’s investments in Senti Biosciences, Pager, Zipdrug, Workit Health, Physera, Mahana Therapeutics, Aptible, Vesta Healthcare and Drone Racing League and has worked with Variant, Strateos and Kyruus.

Prior to joining Lux in 2011, Adam was a Postdoctoral Fellow of Neuroscience at Weill Cornell Medical College, researching regenerative stem cell medicine in association with brain disorders such as schizophrenia and Alzheimer’s disease. Originally from Australia, Adam has dual undergraduate degrees in Business and Science and a PhD from the Australian Stem Cell Centre, where he was a Premier Scholar. He has been published in numerous peer-reviewed, scientific journals.